Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Juno Therapeutics Enters Battle Over CAR Cancer Immunotherapy Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

University of Pennsylvania seeks court order that its cancer immunotherapy does not infringe St. Jude’s patent; Juno, which licensed the patent for the potential leukemia treatment, has joined the settlement talks.

You may also be interested in...



Juno-Novartis CAR-T Settlement Puts Focus Back In Clinic

Novartis agrees to pay Juno an initial $12.25 million, plus future milestone payments and royalties to resolve patent and contract dispute; Juno to share payments with St. Jude.

Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer

A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?

Financings Of The Fortnight Not Seeing A Trickle-Down Investment Effect From Last Year’s IPOs

The 2013 life sciences IPO boom does not necessarily augur more of the same for those biotechs now lining up to go public. Plus financing news from Juno Therapeutics, GlycoMimetics, Ultragenyx and Alkermes.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel